Deal Watch: Teva/Mylan/Perrigo Speculation Pushes Busy Celgene, AstraZeneca Offstage
Executive Summary
AstraZeneca and its large-molecule affiliate MedImmune will partner with Celgene to develop anti-PD-LI immune checkpoint inhibitor MEDI4736. MedImmune also signed combination trial agreements with Juno and Immunocore, while Celgene arranged to buy Quanticel and Mesoblast.